from Cooley

Hong Kong – September 25, 2023 – Cooley advised Wuhan YZY Biopharma, a biotechnology company dedicated to developing bispecific antibody-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic diseases, on its HK$176 million global initial public offering –subject to the exercise of the overallotment option. Partners Ethan Jin and Yiming Liu led the Cooley team.

Wuhan YZY Biopharma offered a total of 11,001,200 H shares, priced at $16 per H share. The listing began trading on the Hong Kong Stock Exchange on September 25, 2023, under the stock code 2496.

China Securities International served as sole sponsor, overall coordinator, joint global coordinator, joint bookrunner and joint lead manager for the global offering. CSCI, Guotai Junan, CCBI, BOCI, TFI Securities, China Galaxy International, Livermore and Futu Securities acted as the international and/or Hong Kong underwriters for the global offering.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.